Berotralstat (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Berotralstat" in German language version.

refsWebsite

Global rank German rank

2^nd place

3^rd place

447^th place

751^st place

4^th place

7^th place

1,610^th place

7,776^th place

5,225^th place

2,461^st place

clinicaltrials.gov

BioCryst Pharmaceuticals: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema. NCT03485911. clinicaltrials.gov, 10. Februar 2021 (clinicaltrials.gov [abgerufen am 14. April 2021]).

Jacqueline R Hwang, Gloria Hwang, Ansh Johri, Timothy Craig: Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema. In: Immunotherapy. Band 11, Nr. 17, 22. Oktober 2019, S. 1439–1444, doi:10.2217/imt-2019-0128.
Bruce Zuraw, William R. Lumry, Douglas T. Johnston, Emel Aygören-Pürsün, Aleena Banerji: Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. In: Journal of Allergy and Clinical Immunology. Band 0, Nr. 0, 20. Oktober 2020, doi:10.1016/j.jaci.2020.10.015, PMID 33098856.
Marie Fahrenhold: HAE-Prophylaxe mit Plasma-Kallikrein-Inhibitor. In: Allergo Journal. Band 27, Nr. 6, 1. September 2018, S. 12–12, doi:10.1007/s15007-018-1682-z.

Center for Drug Evaluation and Research: Drug Trials Snapshot: Orladeyo. In: FDA. 17. Dezember 2020 (fda.gov [abgerufen am 17. April 2021]).

Bruce Zuraw, William R. Lumry, Douglas T. Johnston, Emel Aygören-Pürsün, Aleena Banerji: Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. In: Journal of Allergy and Clinical Immunology. Band 0, Nr. 0, 20. Oktober 2020, doi:10.1016/j.jaci.2020.10.015, PMID 33098856.